Gapping up
In reaction to disappointing earnings/guidance:
- NBEV +18.2%, TNK +7.5%, VIPS +6.5%, EZPW +6.5%, NTES +5.1%, CSCO +4.7%, WUBA +3.2%, SFS +3%, CSIQ +2.5%, WMT +1.6%, TGP +1.2%, .
Other news:
- QURE +25% (initial clinical data in patients treated in the Company's Phase IIb dose-confirmation study of AMT-061 for the treatment of patients with severe and moderately severe hemophilia B)
- ARNA +21.2% (Arena Pharm and United Therapeutics (UTHR) enter into a global license agreement for Arena's ralinepag in development for the treatment of pulmonary arterial hypertension)
- EXEL +5.9% (partner Ipsen receives EC approval for CABOMETYX; triggers $40 mln milestone payment to Exelixis)
- COTY +3.4% (Soros discloses new stake)
- ORCL +3.4% (Berkshire Hathaway discloses new stake in quarterly update)
- SUN +3.3% (American Midstream Partners (AMID) to sell its refined products terminalling business to Sunoco (SUN) for approximately $125 million in cash)
- SVMK +2.4% (continued strength following earnings/Tiger Global stake disclosure)
- JPM +1.6% (Berkshire Hathaway discloses new stake in quarterly update)
- MNK +1.6% (Mallinckrodt's SpecGx confirms outcome of FDA Joint Advisory Committee on abuse-deterrent, immediate-release reformulation of Roxicodone)
- SYMC +1.5% (Starboard, ValueAct and Glenview disclose new holding in quarterly update), ET +1% (after CEO disclosed the purchase of 2 mln shares)
Analyst comments:
- SWCH +3.4% (upgraded to Strong Buy from Mkt Perform at Raymond James)
- CUBE +1.2% (upgraded to Buy from Neutral at BofA/Merrill)
